IGF1 and plasma cell myeloma: Our results confirm the wide-ranging effect of IGF-1 inhibition on myeloma cells, including blockage of the G1 to S phase, reduced PI3K signalling and altered equilibrium of pro- and anti-apoptotic proteins.